Aetna Updated CPB 0055 for Colony-Stimulating Factors — What Billing Teams Need to Know Before October 30, 2025

TL;DR: Aetna, a CVS Health company, modified CPB 0055 governing hematopoietic colony-stimulating factor (CSF) coverage, effective October 30, 2025. If your team bills for filgrastim, pegfilgrastim, or any CSF product — including biosimilars — under Aetna commercial plans, your prior authorization workflows and medical necessity documentation need a review now.

This update to the Aetna colony-stimulating factors coverage policy covers both short-acting and long-acting G-CSF products across nine long-acting and five short-acting branded and biosimilar drugs. CPT 96372 (subcutaneous injection) and CPT 96377 (on-body injector application) are the primary administration codes in scope. The policy applies to commercial medical plans only — for Medicare, Aetna uses separate Part B criteria.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Hematopoietic Colony-Stimulating Factors (CSFs)
Policy Code	CPB 0055 Aetna
Change Type	Modified
Effective Date	October 30, 2025
Impact Level	High
Specialties Affected	Oncology, hematology, bone marrow transplant programs, infusion therapy, specialty pharmacy billing
Key Action	Audit all active CSF prior authorizations and confirm medical necessity documentation meets the updated febrile neutropenia risk criteria before October 30, 2025

---

Aetna Colony-Stimulating Factor Coverage Criteria and Medical Necessity Requirements 2025

The Aetna CSF coverage policy draws hard lines around febrile neutropenia (FN) risk thresholds. Understanding these thresholds is the difference between a clean claim and a denial.

Short-Acting G-CSFs: Granix, Neupogen, Nivestym, Releuko, and Zarxio

Aetna considers short-acting G-CSFs medically necessary for prevention or treatment of febrile neutropenia in cancer patients on myelosuppressive chemotherapy — but only when specific conditions are all met simultaneously.

The policy explicitly names five short-acting G-CSF agents in its medical necessity criteria: Granix (tbo-filgrastim), Neupogen (filgrastim), Nivestym (filgrastim-aafi), Releuko (filgrastim-ayow), and Zarxio (filgrastim-sndz). Nypozi (filgrastim-txid) requires precertification as a short-acting G-CSF but is not explicitly named alongside these five agents in the medical necessity criteria section of the source policy. If you're billing for Nypozi, confirm criteria applicability with Aetna directly before submitting a prior authorization.

Two absolute exclusions apply to every CSF approval:

#	Covered Indication Copy
1	The CSF cannot be used in combination with other colony-stimulating factors in the same chemotherapy cycle.
2	The member cannot receive chemotherapy and radiation therapy at the same time.

If either condition is present, the request does not qualify. Full stop.

Beyond those exclusions, one of three scenarios must apply:

Primary prophylaxis qualifies when the member has a solid tumor or non-myeloid malignancy and is receiving — or will receive — myelosuppressive anti-cancer therapy. The coverage policy then breaks down by FN risk tier:

#	Covered Indication Copy
1	Greater than 20% FN risk: covered for primary prophylaxis.
2	10–20% FN risk: covered only if the member also has bone marrow compromise, significant comorbidities, or other patient-specific risk factors.
3	Less than 10% FN risk: covered only if the member has at least two documented patient-related risk factors.

This tiered structure matters for your medical necessity documentation. A request for primary prophylaxis on a 10–20% risk regimen without documented high-risk comorbidities will not survive a prior authorization review.

Secondary prophylaxis qualifies when the member experienced a febrile neutropenic complication or a dose-limiting neutropenic event during a prior chemotherapy cycle — and the same dose and schedule are planned again, without prior prophylaxis having been given.

Treatment of established neutropenia is also covered under defined criteria. CSFs for treatment of febrile neutropenia should be used only in high-risk patients. The policy references ANC below 100 cells/mm³, uncontrolled primary disease, pneumonia, hypotension, multi-organ dysfunction, or invasive fungal infection as markers of high-risk status.

Long-Acting G-CSFs: Neulasta, Fulphila, Fylnetra, Nyvepria, Rolvedon, Ryzneuta, Stimufend, Udenyca, and Ziextenzo

The long-acting pegfilgrastim products and eflapegrastim (Rolvedon) follow the same FN risk thresholds as short-acting agents. The same primary and secondary prophylaxis logic applies.

Leukine (Sargramostim) — GM-CSF

Sargramostim has the most restricted coverage. Aetna considers it medically necessary only for specific indications including:

Sargramostim for febrile neutropenia prophylaxis in standard chemotherapy patients does not meet Aetna's medical necessity standard under this policy.

Prior Authorization Requirements

Precertification is required for all CSF products — long-acting, short-acting, and sargramostim — under all applicable Aetna commercial plan designs. Call (866) 752-7021 or fax the Statement of Medical Necessity form to (888) 267-3277. Don't assume biosimilar substitution bypasses the prior authorization requirement. Each biosimilar product — Nivestym, Zarxio, Releuko, Nypozi, Fulphila, Fylnetra, and others — carries its own precertification obligation.

---

Aetna Colony-Stimulating Factor Exclusions and Non-Covered Indications

Several CSF indications fall outside Aetna's coverage policy as experimental, investigational, or unproven.

Aetna does not cover CSFs for:

The concurrent radiation/chemotherapy exclusion is one billing teams get caught on. If the oncologist schedules chemoradiation and a CSF on the same claim, you'll likely see a denial. Confirm the treatment plan before submitting.

---

Coverage Indications at a Glance

---

Aetna Colony-Stimulating Factor Billing Guidelines and Action Items 2025

Here's what your billing team needs to do before the October 30, 2025 effective date.

Copy Action Items

If you have a mixed payer patient population and you're unsure how the updated CPB 0055 criteria interact with your oncology service line's current protocols, loop in your compliance officer before October 30, 2025.

---

CPT Codes for Colony-Stimulating Factors Under CPB 0055

Note: CPB 0055 also references 86 HCPCS codes and 215 ICD-10 codes not reproduced here. See the full policy at Aetna.com for the complete code list.

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description
96377	CPT	Application of on-body injector (includes cannula insertion) for timed subcutaneous injection

Other CPT Codes Related to CPB 0055

These codes appear in the policy as contextually related — they represent administration methods and procedures associated with CSF use or the underlying conditions CSFs treat.

Code	Type	Description
36511	CPT	Therapeutic apheresis
36512	CPT	Therapeutic apheresis
36513	CPT	Therapeutic apheresis
36514	CPT	Therapeutic apheresis
36515	CPT	Therapeutic apheresis
36516	CPT	Therapeutic apheresis
38240	CPT	Hematopoietic Progenitor Cell (HPC); allogeneic transplantation per donor
38241	CPT	Autologous transplantation
38242	CPT	Allogeneic lymphocyte infusions
58321	CPT	Artificial insemination; intra-cervical
58322	CPT	Artificial insemination; intra-uterine
96365	CPT	Intravenous infusion
96366	CPT	Intravenous infusion
96367	CPT	Intravenous infusion
96368	CPT	Intravenous infusion
96372	CPT	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular
96401–96463	CPT	Chemotherapy administration (full range)

Note: The full policy includes 168 CPT codes. The chemotherapy administration series (96401–96463) represents the range of administration codes associated with the myelosuppressive regimens that trigger CSF medical necessity criteria.

---